# Polatuzumab Vedotin
Populaarseimad podcastide jaod
Uuendatud:
polatuzumab vedotin, sold under the brand name Polivy, is an antibody-drug conjugate medication used for the treatment of diffuse large B-cell lymphoma (cancer). Polatuzumab is an antibody that targets CD79b, and vedotin is an agent that inhibits cell division by blocking the polymerisation of tubulin.
It was developed by the Genentech subsidiary of Roche.
Diffuse Large B-Cell Lymphoma | Oncology Today with Dr Neil Love: Advances in Diffuse Large B-Cell Lymphoma (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Dr Gilles Salles, including the following topics:
Recent data with polatuzumab vedotin/bendamustine/rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (0:00)
Available data from trials evaluating tafasitamab/lenalid…
Episode 64: Will POLARIX Finally Spell Doom for R-CHOP?
Chadi invites a trio of lymphoma experts to weigh the importance of the POLARIX trial – which was presented at the ASH Annual Meeting and looked at frontline therapy for patients with DLBCL. Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, co-authored publication of the POLARIX study “P…
The Post-POLARIX Trial Era: Polatuzumab Vedotin Shifts DLBCL Treatment
On this episode of The HemOnc Pulse, guest Jonathan Friedberg, MD, MMSc, a hematologic oncologist at the University of Rochester Medicine – Wilmot Cancer Institute, chats with host Dr. Chadi Nabhan on the subtle but important shift in the treatment landscape of diffuse large B-cell lymphoma (DLBCL)…
Diffuse Large B-Cell Lymphoma | Oncology Today with Dr Neil Love: Advances in Diffuse Large B-Cell Lymphoma
Featuring an interview with Dr Gilles Salles, including the following topics:
Biology underlying B-cell lymphomas, role of Bruton tyrosine kinase (BTK) inhibitors in lymphomas and reason for cure in diffuse large B-cell lymphoma (DLBCL) versus indolent lymphomas (0:00)
Efficacy, tolerability an…
Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.
Here are the abstracts that were discussed:
Mantle Cell Lymphoma
1. BOVen trial-A Multicenter Ph…
iwNHL Session V: Novel therapies in NHL - the role of ADCs
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took pl…
Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
Featuring an interview with Dr L Elizabeth Budde, including the following topics:
Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
Use of BsAbs in t…
Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
Featuring an interview with Dr L Elizabeth Budde, including the following topics:
Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
Use of BsAbs in the f…
Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
Featuring an interview with Dr L Elizabeth Budde, including the following topics:
Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
Use of BsAbs in the f…
PODCASTIDE OTSINGUMOOTOR
Saate kasutada meie veebisaiti3,820,986taskuhäälingusaadete ja195,280,751osade otsimiseks inimeste, kohtade või teemade järgi.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
MUUDA
Aitäh, et aitad hoida podcastide andmebaasi ajakohasena.
